Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02985606
Previous Study | Return to List | Next Study

How Does Altering the Timing of Pre-exercise Low-dose Caffeine Ingestion Affect Endurance Exercise Performance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02985606
Recruitment Status : Completed
First Posted : December 7, 2016
Last Update Posted : October 16, 2018
Sponsor:
Information provided by (Responsible Party):
University of Exeter

Brief Summary:
Investigate how manipulating the time between caffeine ingestion and exercise may alter exercise performance and cognition

Condition or disease Intervention/treatment Phase
Healthy Other: Caffeine powder -60 Other: Caffeine powder -30 Other: Caffeine powder 0 Other: Placebo powder -60 Other: Placebo powder -30 Other: Placebo powder 0 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: How Does Altering the Timing of Pre-exercise Low-dose Caffeine Ingestion Affect Endurance Exercise Performance
Study Start Date : November 2016
Actual Primary Completion Date : June 30, 2017
Actual Study Completion Date : September 15, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Caffeine -60
Caffeine at 60 minutes prior to time trial
Other: Caffeine powder -60
Other: Placebo powder -30
Other: Placebo powder 0
Active Comparator: Caffeine -30
Caffeine at 30 minutes prior to time trial
Other: Caffeine powder -30
Other: Placebo powder -60
Other: Placebo powder 0
Active Comparator: Caffeine 0
Caffeine immediately prior to time trial
Other: Caffeine powder 0
Other: Placebo powder -60
Other: Placebo powder -30
Placebo Comparator: Placebo
Placebo drink at all time points
Other: Placebo powder -60
Other: Placebo powder -30
Other: Placebo powder 0



Primary Outcome Measures :
  1. Work done in kilojoules (kJ) during a 15 minute time trial on a cycle ergometer [ Time Frame: 15 minutes ]

Secondary Outcome Measures :
  1. Whole body fuel substrate utilisation measured using indirect calorimetry [ Time Frame: 10 minutes ]
  2. Change in plasma caffeine concentration and metabolites [ Time Frame: 2 hours 45 minutes ]
  3. Change in cognitive function measured using stroop test [ Time Frame: 2 hours 45 minutes ]
  4. Collection of saliva for genotyping of CYP1A2 [ Time Frame: 30 mintes ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • vo2max > 55 ml/kg/min
  • females on contraceptive pill

Exclusion Criteria:

  • recent skeletal muscle injury
  • cardiovascular injury
  • metabolic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02985606


Locations
Layout table for location information
United Kingdom
Sport and Health Sciences
Exeter, Devon, United Kingdom, EX1 2LU
Sponsors and Collaborators
University of Exeter
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Exeter
ClinicalTrials.gov Identifier: NCT02985606    
Other Study ID Numbers: 181739/02
First Posted: December 7, 2016    Key Record Dates
Last Update Posted: October 16, 2018
Last Verified: October 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents